Clene to Present at Emerging Growth Conference, October 23, 2025.
ByAinvest
Monday, Oct 20, 2025 8:30 pm ET1min read
CLNN--
Clene Inc. and its wholly-owned subsidiary Clene Nanomedicine Inc. focus on improving mitochondrial health and protecting neuronal function. Their lead candidate, CNM-Au8®, is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
The Emerging Growth Conference is an effective platform for public companies to present their new products and services to the investment community. The conference will be conducted through video webcasts and will take place in the Eastern time zone. The audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.
Clene Inc. has a strong pipeline of clinical trials and has shown promising results in its Phase 2/3 studies. The company has scheduled key FDA meetings to discuss its ALS treatment program and plans to submit a New Drug Application (NDA) in Q4 2025 for potential accelerated approval. In its recent financial results, the company reported a cash position of $7.3 million as of June 30, 2025, with additional funds raised post-quarter, providing runway into Q1 2026.
For more information about Clene Inc. and its subsidiaries, visit their website at www.clene.com or follow them on X (formerly Twitter) and LinkedIn.
Clene Inc. will present at the Emerging Growth Conference on October 23, 2025, at 3:10 p.m. ET. The virtual presentation will cover a corporate update and will be available on Clene's website and the Emerging Growth YouTube Channel. Clene is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company, will present a corporate update at the Emerging Growth Conference on October 23, 2025, at 3:10 p.m. ET. The virtual presentation will cover the company's progress in developing treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. The presentation will be available on Clene's website and the Emerging Growth YouTube Channel.Clene Inc. and its wholly-owned subsidiary Clene Nanomedicine Inc. focus on improving mitochondrial health and protecting neuronal function. Their lead candidate, CNM-Au8®, is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
The Emerging Growth Conference is an effective platform for public companies to present their new products and services to the investment community. The conference will be conducted through video webcasts and will take place in the Eastern time zone. The audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.
Clene Inc. has a strong pipeline of clinical trials and has shown promising results in its Phase 2/3 studies. The company has scheduled key FDA meetings to discuss its ALS treatment program and plans to submit a New Drug Application (NDA) in Q4 2025 for potential accelerated approval. In its recent financial results, the company reported a cash position of $7.3 million as of June 30, 2025, with additional funds raised post-quarter, providing runway into Q1 2026.
For more information about Clene Inc. and its subsidiaries, visit their website at www.clene.com or follow them on X (formerly Twitter) and LinkedIn.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet